

**Supplementary**

**Table S1** Sensitivity analysis excluding patients not treated with neoadjuvant FOLFIRINOX—HR of progression for patients treated with chemoradiation with concurrent CAPE or GEM with or without resectable patients in analysis

Concurrent Chemo	Borderline resectable and resectable		Borderline resectable only	
	HR (95% CI, %)	AHR (95% CI, %)	HR (95% CI, %)	AHR (95% CI, %)
GEM	Ref.	Ref.	Ref.	Ref.
Xeloda	0.42 (0.13 1.35)	0.35 (0.08 1.53)	0.50 (0.15 1.63)	0.35 (0.09 1.42)

AHR is adjusted by age at diagnosis, weeks of neoadjuvant chemotherapy, and performance status. HR, hazard ratio; CAPE, capecitabine; GEM, gemcitabine; AHR, adjusted hazard ratio; CI, confidence interval; Chemo, chemotherapy.

**Table S2** Sensitivity analysis excluding patients not treated with neoadjuvant FOLFIRINOX—HR of death for patients treated with chemoradiation with concurrent Xeloda or GEM with or without resectable patients in analysis

Concurrent Chemo	Borderline resectable and resectable		Borderline resectable Only	
	HR (95% CI, %)	AHR (95% CI, %)	HR (95% CI, %)	AHR (95% CI, %)
GEM	Ref.	Ref.	Ref.	Ref.
Xeloda	0.32 (0.08–1.31)	0.32 (0.06–1.86)	0.42 (0.10–1.68)	0.34 (0.06–1.83)

AHR is adjusted by age at diagnosis, weeks of neoadjuvant chemotherapy, and performance status. HR, hazard ratio; GEM, gemcitabine; AHR, adjusted hazard ratio; CI, confidence interval; Chemo, chemotherapy.